Cannabinoid Derived Articles & Analysis
14 news found
KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse neuropathic pain in pre-clinical animal studies. ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the European Medicines Agency (EMA) has classified PPP004 as an orphan medicinal product for the treatment for epidermolysis bullosa (EB). ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development in collaboration with Panag, a subsidiary of Tetra Bio-Pharma, and True North Cannabis Corp (True North), today announced it has entered into a technology licensing agreement allowing True North to use its highly innovative proprietary ...
The publication centered on pre-clinical research for its proprietary, cannabinoid-derived analog KLS-13019 showing both the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN). ...
Neuropathix has designated proprietary, cannabinoid-derivative compound KLS-13019 as lead drug candidate for the treatment of neuropathic pain, a viable alternative to opioids. ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that Health Canada approved the amendment of a phase I study conducted in collaboration with Dr. ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development announced today that it has executed a non-binding term sheet with Avicanna Inc. ...
That is the very essence of drug discovery and pointedly in the now emerging field of cannabinoid therapeutics. We believe that this acknowledgment starts with patent awards from scientifically advanced markets like India. ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of its marketed public offering (the "Offering") of 13,064,000 units of the Company (the "Units"), at a price of $0.163 per Unit for aggregate gross proceeds of $2.1 million. ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced positive initial clinical data from its ongoing Phase 2 clinical trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for cancer pain. ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that it received a letter from the United States Food and Drug Administration (FDA), granting a Type C meeting to discuss safety and labelling requirements for obtaining marketing approval under the 505(b)(1) regulatory ...
Purisys has extensive experience in the synthetic manufacture and analytical testing of cannabinoid related compounds. Because of the extent of Purisys’ knowledge and experience in the field of producing bulk synthetic APIs as well as its well documented expertise in the manufacture of synthetic cannabinoids, we believe Purisys will be able to leverage ...
("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational drug, QIXLEEF™. ...
Sara Jane Ward and her research team at Temple University for their invaluable contribution to life sciences, the cannabinoid-based therapeutics space, and belief in the potential of KLS-13019. ...